Bristol Myers Squibb Rating Reiterated by TheStreet (BMY)
Bristol Myers Squibb (NYSE: BMY)‘s stock had its “buy” rating restated by analysts at TheStreet in a research report issued to clients and investors on Thursday.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of A- . The company’s strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
BMY has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note to investors on Wednesday. They now have a $40.00 price target on the stock. Separately, analysts at William Blair initiated coverage on shares of Bristol Myers Squibb in a research note to investors on Tuesday, March 5th. They set an “outperform” rating on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note to investors on Tuesday, March 5th. They now have a $34.00 price target on the stock.
Six equities research analysts have rated the stock with a buy rating, one has assigned an overweight rating, fifteen have issued a hold rating, and one has issued a sell rating to the company. Bristol Myers Squibb currently has an average rating of “hold” and an average price target of $35.83.
Bristol Myers Squibb traded down 0.62% on Thursday, hitting $38.25. Bristol Myers Squibb has a 52-week low of $30.64 and a 52-week high of $38.57. The stock’s 50-day moving average is currently $36.81. The company has a market cap of $62.629 billion and a price-to-earnings ratio of 33.18.
Bristol Myers Squibb last posted its quarterly earnings results on Thursday, January 24th. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.42 by $0.05. The company had revenue of $4.19 billion for the quarter, compared to the consensus estimate of $4.14 billion. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was down 23.2% on a year-over-year basis. Bristol Myers Squibb has set its FY13 guidance at $1.78-1.88 EPS. On average, analysts predict that Bristol Myers Squibb will post $1.84 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 3.64%. The ex-dividend date is Wednesday, April 3rd.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.